Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic
Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/2/127 |
| _version_ | 1797520751799042048 |
|---|---|
| author | Tabitha Tse Sandeep Sehdev Jean Seely Denis H. Gravel Mark Clemons Erin Cordeiro Angel Arnaout |
| author_facet | Tabitha Tse Sandeep Sehdev Jean Seely Denis H. Gravel Mark Clemons Erin Cordeiro Angel Arnaout |
| author_sort | Tabitha Tse |
| collection | DOAJ |
| description | Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging purposes. However, it does also offer patients with certain biologic subtypes such as the triple negative or Her2 positive breast cancers the opportunity to improve survival, even in early stage disease. During the height of the pandemic, an opportunity and motivation for the increased use of neoadjuvant therapy in breast cancer was identified. This paper describes the conditions that have supported this practice change at the provider and institutional levels. We also include our own institutional algorithm based on tumor biology and extent of disease that have guided our decisions on breast cancer management during the pandemic. Our processes can be adapted by other institutions and breast oncology practices in accordance with local conditions and resources, during and beyond the pandemic. |
| first_indexed | 2024-03-10T08:01:04Z |
| format | Article |
| id | doaj.art-7a41572d606e4ae2afeb7ad5a66503c8 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:01:04Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-7a41572d606e4ae2afeb7ad5a66503c82023-11-22T11:28:04ZengMDPI AGCurrent Oncology1198-00521718-77292021-03-012821338134710.3390/curroncol28020127Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global PandemicTabitha Tse0Sandeep Sehdev1Jean Seely2Denis H. Gravel3Mark Clemons4Erin Cordeiro5Angel Arnaout6Department of Surgery, Grand River Hospital, Kitchener Waterloo, ON N2G 1G3, CanadaDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, CanadaDivision of Breast Imaging, Department of Diagnostic Imaging, University of Ottawa, Ottawa, ON K1H 8L6, CanadaDepartment of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON K1H 8L6, CanadaDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, CanadaDivision of General Surgery, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, CanadaDivision of General Surgery, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, CanadaPractice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging purposes. However, it does also offer patients with certain biologic subtypes such as the triple negative or Her2 positive breast cancers the opportunity to improve survival, even in early stage disease. During the height of the pandemic, an opportunity and motivation for the increased use of neoadjuvant therapy in breast cancer was identified. This paper describes the conditions that have supported this practice change at the provider and institutional levels. We also include our own institutional algorithm based on tumor biology and extent of disease that have guided our decisions on breast cancer management during the pandemic. Our processes can be adapted by other institutions and breast oncology practices in accordance with local conditions and resources, during and beyond the pandemic.https://www.mdpi.com/1718-7729/28/2/127breast cancerneoadjuvant chemotherapypandemicpractice change |
| spellingShingle | Tabitha Tse Sandeep Sehdev Jean Seely Denis H. Gravel Mark Clemons Erin Cordeiro Angel Arnaout Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic Current Oncology breast cancer neoadjuvant chemotherapy pandemic practice change |
| title | Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic |
| title_full | Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic |
| title_fullStr | Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic |
| title_full_unstemmed | Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic |
| title_short | Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic |
| title_sort | neoadjuvant chemotherapy in breast cancer review of the evidence and conditions that facilitated its use during the global pandemic |
| topic | breast cancer neoadjuvant chemotherapy pandemic practice change |
| url | https://www.mdpi.com/1718-7729/28/2/127 |
| work_keys_str_mv | AT tabithatse neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT sandeepsehdev neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT jeanseely neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT denishgravel neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT markclemons neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT erincordeiro neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic AT angelarnaout neoadjuvantchemotherapyinbreastcancerreviewoftheevidenceandconditionsthatfacilitateditsuseduringtheglobalpandemic |